Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Gastrointestinal 22Genitourinary 16Breast 15Gynecologic 5Thoracic 3Other solid neoplasm 2Tumor-Agnostic 1Head & Neck 1

Conditions

Solid Tumor 1HER2 1

Interventions

Cisplatin 147pembrolizumab 129Carboplatin 126Injections 108Pemetrexed 99Paclitaxel 97Gemcitabine 85Irinotecan 75Cyclophosphamide 72Nivolumab 71Docetaxel 68Bevacizumab 59Oxaliplatin 50Fluorouracil 50Capecitabine 48atezolizumab 46Leucovorin 42Etoposide 42tislelizumab 40toripalimab 36fludarabine 32Drug Therapy 32Ipilimumab 30Topotecan 29durvalumab 28Vincristine 27Specimen Handling 27Early Intervention, Educational 27Radiotherapy 26Interviews as Topic 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
disitamab vedotin × Other solid neoplasm × Clear all
NCT05940896 2023-11-27

RC48-ADC Combined With Radiotherapy in the Treatment of Locally Advanced Solid Tumors With HER2 Expression

RemeGen Co., Ltd.

Phase 1 Recruiting
24 enrolled
Other solid neoplasm

Solid Tumor

NCT05649163 2022-12-16

Real-world Study of HER2-overexpressed Advanced Solid Tumors After Progression of First-line Standard Therapy

Peking University

Unknown
306 enrolled
GastrointestinalOther solid neoplasm

HER2

Data powered by HemOnc (CC BY 4.0) Colophon âš¡